InVivoMAb anti-mouse MHC Class I (H-2Kk, H-2Dk)

Clone Catalog # Category
16-1-2N (HB14) BE0228 InVivoMab Antibodies
$95 - $3250

About InVivoMAb anti-mouse MHC Class I (H-2Kk, H-2Dk)

The 16-1-2N monoclonal antibody is reported to react with the mouse H-2Kk and H-2Dk MHC class I alloantigens. MHC class I antigens are heterodimers consisting of one alpha chain (44 kDa) associated with β2 microglobulin (11.5 kDa). The antigen is expressed by all nucleated cells at varying levels. MHC Class I molecules present endogenously synthesized antigenic peptides to CD8 T cells.

InVivoMAb anti-mouse MHC Class I (H-2Kk, H-2Dk) Specifications

Isotype

Mouse IgG2a

Recommended Isotype Control(s) InVivoMAb mouse IgG2a isotype control, unknown specificity(BE0085)
Recommended InVivoPure Dilution Buffer InVivoPure pH 7.0 Dilution Buffer(IP0070)
Immunogen

C3H mouse spleen cells

Reported Applications
  • Functional assays
  • Flow cytometry
Endotoxin
  • <2EU/mg (<0.002EU/μg)
  • Determined by LAL gel clotting assay
Purity
  • >95%
  • Determined by SDS-PAGE
Formulation
  • PBS, pH 7.0
  • Contains no stabilizers or preservatives
Sterility

0.2 μM filtered

Production

Purified from tissue culture supernatant in an animal free facility

Purification

Protein G

Storage

The antibody solution should be stored at the stock concentration at 4°C. Do not freeze.

RRID

AB_2687711

Molecular Weight

150 kDa

Application References

InVivoMAb anti-mouse MHC Class I (H-2Kk, H-2Dk) (Clone: 16-1-2N (HB14))

Jiang, H., et al. (1998). "T cell vaccination induces T cell receptor Vbeta-specific Qa-1-restricted regulatory CD8(+) T cells." Proc Natl Acad Sci U S A 95(8): 4533-4537. PubMed

Vaccination of mice with activated autoantigen-reactive CD4(+) T cells (T cell vaccination, TCV) has been shown to induce protection from the subsequent induction of a variety of experimental autoimmune diseases, including experimental allergic encephalomyelitis (EAE). Although the mechanisms involved in TCV-mediated protection are not completely known, there is some evidence that TCV induces CD8(+) regulatory T cells that are specific for pathogenic CD4(+) T cells. Previously, we demonstrated that, after superantigen administration in vivo, CD8(+) T cells emerge that preferentially lyse and regulate activated autologous CD4(+) T cells in a T cell receptor (TCR) Vbeta-specific manner. This TCR Vbeta-specific regulation is not observed in beta2-microglobulin-deficient mice and is inhibited, in vitro, by antibody to Qa-1. We now show that similar Vbeta8-specific Qa-1-restricted CD8(+) T cells are also induced by TCV with activated CD4(+) Vbeta8(+) T cells. These CD8(+) T cells specifically lyse murine or human transfectants coexpressing Qa-1 and murine TCR Vbeta8. Further, CD8(+) T cell hybridoma clones generated from B10.PL mice vaccinated with a myelin basic protein-specific CD4(+)Vbeta8(+) T cell clone specifically recognize other CD4(+) T cells and T cell tumors that express Vbeta8 and the syngeneic Qa-1(a) but not the allogeneic Qa-1(b) molecule. Thus, Vbeta-specific Qa-1-restricted CD8(+) T cells are induced by activated CD4(+) T cells. We suggest that these CD8(+) T cells may function to specifically regulate activated CD4(+) T cells during immune responses.

Kusunoki, Y., et al. (1998). "Prevention of marrow graft rejection without induction of graft-versus-host disease by a cytotoxic T-cell clone that recognizes recipient alloantigens." Blood 91(11): 4038-4044. PubMed

In allogeneic marrow transplantation, donor T cells that recognize recipient alloantigens prevent rejection but also cause graft-versus-host disease (GVHD). To evaluate whether the ability to prevent marrow graft rejection could be dissociated from the ability to cause GVHD, we generated a panel of four different CD8 cytotoxic T-lymphocyte clones specific for H2(d) alloantigens. Three of the clones caused no overt toxicity when as many as 20 x 10(6) cells were infused intravenously into irradiated H2(d)-positive recipients, and one clone caused acute lethal toxicity within 1 to 3 days after transferring 10 x 10(6) cells into H2(d)-positive recipients. One clone that did not cause toxicity was able to prevent rejection of (C57BL/6J x C3H/HeJ)F1 marrow in 800 cGy-irradiated (BALB/cJ x C57BL/6J)F1 recipients without causing GVHD. Large numbers of cells and exogenously administered interleukin-2 were required to prevent rejection. These results with different CD8 clones suggest that GVHD and prevention of rejection could be separable effects mediated by distinct populations of donor T cells that recognize recipient alloantigens.

O'Neill, H. C. (1986). "Monoclonal antibodies specific for H-2K and H-2D antigens on cytotoxic T cells can inhibit their function." Proc Natl Acad Sci U S A 83(5): 1443-1447. PubMed

Antibodies specific for murine major histocompatibility gene complex (MHC) class I H-2K and H-2D molecules present on cytotoxic T (Tc) cells have been shown to inhibit their function of target cell lysis. This could only be demonstrated by using a more sensitive assay for T-cell-mediated lysis, and many monoclonal antibodies of different Ig class, origin, and specificity can be shown to inhibit alloreactive as well as MHC-restricted Tc cells. These antibodies inhibit different activated T-cell populations to varying extents, and anti-H-2K but not anti-H-2D antibodies show a synergistic effect with anti-Lyt-2 antibodies. Data here suggest that MHC molecules may be located in or near the T-cell receptor complex on these cells.

       

We're Heading to AACR

Come visit us at Booth 1842! See you in Atlanta!